reports
- Jonathan Moreland
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HT...
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need ~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated signifi...
Corcept Therapeutics Inc: 4 directors
Four Directors at Corcept Therapeutics Inc sold after exercising options/sold 85,000 shares at between 70.250USD and 70.526USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Und...
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of its previously announced underwrit...
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Und...
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an upsized underwritten public offering of 9,803,921 shares of its common stock at a public offering price of $2...
Mineralys Therapeutics Announces Proposed Public Offering of Common St...
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $175.0 million of shares of its common stock. In addition, Mineralys expects to grant the underwriters a 30-...
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results a...
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference...
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Resul...
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on...
Mineralys Therapeutics Announces Journal of the American Medical Assoc...
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat – The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 – – Lorundrostat was generally well-tolerated; and treatment-emergent adverse events were mostly mild, ...
Mineralys Therapeutics Announces Positive Topline Results from Phase 2...
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p6.0 mmol/L)0/59 (0%)3/58 (5%) BP, blood pressure; UACR, Urine albumin-to-creatinine ratio;...
Mineralys Therapeutics Announces Late-Breaking Presentation of Data fr...
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) – Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmH...
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3...
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the trea...
Mineralys Therapeutics Reports First Quarter 2025 Financial Results an...
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focuse...
Mineralys Therapeutics to Participate in the Bank of America Securitie...
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. Bank of America Securities Health ...
Mineralys Therapeutics to Announce First Quarter 2025 Financial Result...
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May ...
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advanc...
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) – Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – – Detailed results from the second pivotal Phase 3 Launch-HTN trial to be presented at an upcoming medical conference and published in a peer-reviewed publication – RADNOR, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS)...
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN P...
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) – Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – ...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
ULTA ULTA BEAUTY INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TITN TITAN MACHINERY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
MCHX MARCHEX INC. CL B
IMMR IMMERSION CORP.
HSC HARSCO CORPORATION
GOGO GOGO INC.
GCO GENESCO INC.
FGEN FIBROGEN INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
LIVE LIVE VENTURES
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
TROX TRONOX HOLDINGS PLC
AEYE AUDIOEYE INC
ZYME ZYMEWORKS INC.
GRWG GROWGENERATION
PRLD PRELUDE THERAPEUTICS
FTHM FATHOM HOLDINGS
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
TOI ONCOLOGY INSTITUTE INC (THE)
HD HOME DEPOT
BTMD INC.
BLIN HAYMAKER ACQUISITION CORP III
BUKS BRIDGELINE DIGITAL INC
MODD BUTLER NATIONAL CORP
MLYS MODULAR MEDICAL INC
WEST MINERALYS THERAPEUTICS INC
SRFM WESTROCK COFFEE COMPANY LLC
GUTS SURF AIR MOBILITY INC.
ADVM FRACTYL HEALTH INC
AFCG ADVERUM BIOTECHNOLOGIES INC.
FG AFC GAMMA
EU INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from ...
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driv...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
SRE SEMPRA ENERGY
PSEC PROSPECT CAPITAL CORPORATION
ORRF ORRSTOWN FINANCIAL SERVICES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
HSC HARSCO CORPORATION
GOGO GOGO INC.
FRPT FRESHPET INC
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
CMCO COLUMBUS MCKINNON CORPORATION
MAC MACERICH COMPANY
PETS PETMED EXPRESS INC.
TREE LENDINGTREE INC.
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
FTHM FATHOM HOLDINGS
CLVT CLARIVATE PLC
LYEL LYELL IMMUNOPHARMA INC
FLNC FLUENCE ENERGY INC
HD HOME DEPOT
BTMD INC.
ECAT HAYMAKER ACQUISITION CORP III
BUKS BLACKROCK ESG CAP ALLOCATION TR
ONL BUTLER NATIONAL CORP
MLYS ORION OFFICE REIT INC
WEST MINERALYS THERAPEUTICS INC
SBGI WESTROCK COFFEE COMPANY LLC
DK SINCLAIR INC
CVI DELEK US HOLDINGS
SRBK INC.
GUTS CVR ENERGY
ADVM INC.
SUNS SR BANCORP INC
AFCG FRACTYL HEALTH INC
ADVERUM BIOTECHNOLOGIES INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.